Article
Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses.
Journal of immunology (Baltimore, Md. : 1950) - 1 Dec 2007
Stolina Marina, Dwyer Denise, Ominsky Michael S, Corbin Timothy, Van Gwyneth, Bolon Brad, Sarosi Ildiko, McCabe James, Zack Debra J, Kostenuik Paul
Abstract excerpt
Receptor activator of NF-kappaB ligand (RANKL) is an essential mediator of osteoclast formation, function, and survival. The effects of RANKL are inhibited by a soluble decoy receptor called osteoprotegerin (OPG). Total ablation of RANKL in knockout mice leads to high bone mass, lymph node agenesis, and altered lymphocyte differentiation. In contrast, RANKL inhibition via OPG suppresses bone resorption but not...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.